Breast Cancer Articles

Breast Cancer Stem Cell Research Burgeoning With Vaccines, Epigenetic Therapeutic Developments
Max Wicha, MD, shares insight on the intriguing research being conducted on breast cancer stem cells.
Evolution of Genetic Testing in Breast Cancer Continues
Michael Simon, MD, MPH, discusses advances in genetic testing for breast cancer, highlighting the overlap between genomic risk assessment and tumor genomic profiling.
Patients Aged <65 Years Face Higher Costs for Treatment of 4 Common Cancers
Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.
Lisa A. Newman, MD, discusses de-escalation strategies emerging in breast cancer surgery.
Expert Recaps Radiation Refinements in Breast Cancer
Eleanor M. Walker, MD, discusses advances in radiation therapy in breast cancer and the rationale for hypofractionated scheduling.
FDA Grants Talazoparib Priority Review for BRCA+ Breast Cancer
The FDA has granted a priority review to a new drug application for talazoparib for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer.
Niraparib/Pembrolizumab Combo Active in Relapsed, Progressive TNBC
Half of patients with metastatic triple-negative breast cancer achieved disease control when treated with the combination of niraparib (Zejula) and pembrolizumab (Keytruda). 
Early OS Data Support Phase III Trial With AKT Inhibitor Ipatasertib for TNBC
First-line treatment with the oral AKT inhibitor ipatasertib shows a promising trend toward improving overall survival when added to paclitaxel for the treatment of locally advanced or metastatic triple-negative breast cancer.
Ribociclib Prolongs PFS With Fulvestrant in First- or Second-Line HR-Positive, HER2-Negative Advanced Breast Cancer
Adding the CDK4/6 inhibitor ribociclib to fulvestrant significantly prolonged progression-free survival in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no or 1 prior line of therapy.
Endocrine Therapy Alone Is Sufficient in HR+/HER2- Breast Cancer With Intermediate Recurrence Score
Adjuvant endocrine therapy alone is noninferior to adjuvant chemoendocrine therapy in patients with hormone receptor–positive, HER2-negative, node-negative early-stage breast cancer.
Publication Bottom Border
Border Publication